Blueprint Medicines Corp. (2L9)

Overview

Blueprint Medicines Corporation is a precision therapy company focused on developing innovative treatments for genomically defined cancers and blood disorders. With operations both in the United States and internationally, the company pioneers in creating targeted therapies aimed at addressing specific genetic markers within cancerous cells and blood disorders. Initially founded as Hoyle Pharmaceuticals, Inc., it underwent a name change to Blueprint Medicines Corporation in June 2011 and has been advancing in the field of precision medicine since its inception in 2008. Headquartered in Cambridge, Massachusetts, Blueprint Medicines is at the forefront of developing a new wave of targeted therapies aimed at improving the lives of patients with serious genetic diseases.

Products and Services

Blueprint Medicines Corporation's pipeline includes several promising investigational drugs in various stages of development, targeting a range of conditions with significant unmet medical needs:

• AYVAKIT: In development for systemic mastocytosis (SM) and gastrointestinal stromal tumors, AYVAKIT represents the company's dedication to addressing rare and hard-to-treat cancers by targeting specific genetic mutations.
• BLU-263: An orally available KIT inhibitor, BLU-263 is being developed for the treatment of indolent systemic mastocytosis and other mast cell disorders, showcasing the company's focus on precision medicine in the realm of rare blood disorders.
• GAVRETO: Targeting RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma, GAVRETO exemplifies Blueprint Medicines’ commitment to lung and thyroid cancer patients with specific genetic alterations.
• BLU-945: Addressing epidermal growth factor receptor (EGFR) driven non-small-cell lung carcinoma (NSCLC), BLU-945 is tailored for patients with specific EGFR mutations, highlighting the company's efforts in lung cancer precision therapy.
• BLU-451: Specifically in development for NSCLC patients with EGFR exon 20 insertion mutations, BLU-451 adds to the company's portfolio of targeted lung cancer therapies.
• BLU-782: Aimed at fibrodysplasia ossificans progressiva, BLU-782 is an example of the company's innovative approach to rare diseases, focusing on conditions with critical needs for effective treatments.
• BLU-222: This investigational drug is targeted towards patients with cyclin E aberrant cancers, further expanding Blueprint Medicines' oncology pipeline with a focus on precision oncology.
• BLU-852: Developed for the treatment of advanced cancers, BLU-852 represents the company's broader efforts in tackling various types of advanced-stage malignancies with novel therapeutic approaches.

Additionally, Blueprint Medicines Corporation has forged several strategic collaboration and license agreements to enhance its developmental capabilities and reach. Partnerships with entities like Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd., underline the company's commitment to bringing new, groundbreaking therapies to market through cooperative efforts and shared expertise.